SINGAPORE & OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) will present data from two global Phase 3 double-blind, placebo-controlled studies of oveporexton (TAK-861) 1, ...

The Allen Institute for AI (Ai2) hopes to take advantage of an increased demand for customized models and enterprises seeking more transparency from AI models with its latest release. Ai2 made the ...

The failure of Regeneron’s “defining catalyst” of the first half of the year puts fresh pressure on the company, analysts said. (iStock / Getty Images Plus) A phase 3 trial of Regeneron’s LAG-3 ...

FDA clearance received to start the pivotal, 500-patient, placebo-controlled Phase 3 “PREVAiLS” study of pridopidine in participants with early, rapidly progressive ALS; US recruitment set to begin ...